Skip to main content

Table 2 Apoptosis and proliferation in cell tumour experiments

From: Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo

Cell line

Control

Treated R115777

  

50 mg/kg

100 mg/kg

MCF-7/HER2-18

   

   Ki67 (%)

77.7 (74.4–81.1)

69.6** (63.4–74.8)

65.5**** (62.0–70.1)

   TUNEL (%)

1.2 (0.9–1.5)

1.5* (1.2–1.6)

1.6** (1.4–1.9)

   CTI

61.6 (55.5–79.5).

48.7*** (41.6–57.4)

38.0**** (30.1–43.3)

SKOV3

   

   Ki67 (%)

46.6 (32.0–63.8)

34.1** (20.3–57.2)

40.1 (26.6–48.8)

   TUNEL (%)

0.35 (0.1–0.8)

0.49 (0.1–1.0)

0.48 (0.1–1.4)

   CTI

125.4 (87.1–188.9).

67.5**(45.6–96.1)

81.0* (38.6–110.2)

MDA-MB231

   

   Ki67 (%)

61.7 (54.1–74.6)

69.3 (56.1–78.0)

72.4* (43.8–83.1)

   TUNEL (%)

0.55 (0.3–0.9)

0.45 (0.3–0.6)

0.31* (0.1–0.4)

   CTI

106.0 (85.8–191.0).

180.1 (115.9–205.4)

180.8 (90.5–227.7)

  1. Effect of R115777 on proliferation (Ki67), apoptosis (TdT-mediated dUTP-fluorescence nick end labelling [TUNEL]) and cell turnover index (CTI) in cell line tumours grown in athymic nude mice. Values are expressed as median values (interquartile range). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.